コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 uded (23 controls, 30 prodromal and 25 overt alpha-synucleinopathies).
2 ardinal features of autonomic dysfunction in alpha-synucleinopathy.
3 mmals have different mechanisms to forestall alpha-synucleinopathy.
4 abundant in PAF, a predominantly peripheral alpha-synucleinopathy.
5 atment, or whether it harbours an underlying alpha-synucleinopathy.
6 ith neurite pathology is causally related to alpha-synucleinopathy.
7 s with psy-RBD are familially predisposed to alpha-synucleinopathy.
8 yn degradation pathways is needed to address alpha-synucleinopathy.
9 demonstrate a familial predisposition to an alpha-synucleinopathy.
10 n postmortem brain tissue from patients with alpha-synucleinopathy.
11 ncluding TDP-43 proteinopathy, tauopathy and alpha-synucleinopathy.
12 and in situ studies of human specimens with alpha-synucleinopathy.
13 a key neurodegenerative mechanism underlying alpha-synucleinopathy.
14 2-tailed t test; P = .04) and more frequent alpha-synucleinopathy.
15 pecies generation, could be major players in alpha-synucleinopathy.
16 ERS could contribute to neurodegeneration in alpha-synucleinopathy.
17 oligomers in mouse and human brain with the alpha-synucleinopathy.
18 degeneration in Parkinson's disease (PD) and alpha-synucleinopathy.
19 he formation of inclusions in PD and related alpha synucleinopathies.
20 athogenesis of Parkinson's disease and other alpha-synucleinopathies.
21 enesis of Parkinson's disease (PD) and other alpha-synucleinopathies.
22 a significant factor in the pathogenesis of alpha-synucleinopathies.
23 transgenic mouse model of neurodegenerative alpha-synucleinopathies.
24 features with relevant clinical outcomes in alpha-synucleinopathies.
25 e and points to shared disease mechanisms in alpha-synucleinopathies.
26 ent sleep behavior disorder is a prodrome of alpha-synucleinopathies.
27 for the treatment of PD as well as the other alpha-synucleinopathies.
28 sequent neuroprotection with implications to alpha-synucleinopathies.
29 isorder (iRBD) are in the prodromal stage of alpha-synucleinopathies.
30 that often predicts the later occurrence of alpha-synucleinopathies.
31 alpha-synuclein ubiquitination in models of alpha-synucleinopathies.
32 tion in Parkinson's disease (PD) and related alpha-synucleinopathies.
33 eneration in Parkinson's disease and related alpha-synucleinopathies.
34 ther STING is activated in or contributes to alpha-synucleinopathies.
35 P13 is a potential therapeutic target in the alpha-synucleinopathies.
36 ion from the prodromal to the overt stage of alpha-synucleinopathies.
37 feature of lipid aberration in PD and other alpha-synucleinopathies.
38 luding tauopathies, Huntington's disease and alpha-synucleinopathies.
39 odegenerative diseases known collectively as alpha-synucleinopathies.
40 ogression of Parkinson's disease and related alpha-synucleinopathies.
41 based, 1991 to 2010 incident-cohort study of alpha-synucleinopathies.
42 ifying therapeutic strategy for PD and other alpha-synucleinopathies.
43 hogenesis of Parkinson's disease and related alpha-synucleinopathies.
44 herefore, MSA is included in the category of alpha-synucleinopathies.
45 ed to slow the progression of PD and related alpha-synucleinopathies.
46 n how it evades sHsp chaperone action in the alpha-synucleinopathies.
47 ogic hallmarks of Parkinson disease (PD) and alpha-synucleinopathies.
48 tential disease indicator for PD and related alpha-synucleinopathies.
49 ve diseases, collectively referred to as the alpha-synucleinopathies.
50 s for monomeric alpha-syn in PD and in other alpha-synucleinopathies.
51 constipation in Parkinson disease and other alpha-synucleinopathies.
52 of Lewy body inclusions in neurodegenerative alpha-synucleinopathies.
53 ation for the treatment of the yet incurable alpha-synucleinopathies.
54 ark lesions in Parkinson's disease and other alpha-synucleinopathies.
55 y to degrade alpha-synuclein in PD and other alpha-synucleinopathies.
56 ocessing and may modulate the progression of alpha-synucleinopathies.
57 uld be an effective therapy for PD and other alpha-synucleinopathies.
58 ration in Parkinson's disease (PD) and other alpha-synucleinopathies.
59 ions that contribute to neurodegeneration in alpha-synucleinopathies.
60 pathogenesis of Parkinson disease and other alpha-synucleinopathies.
61 r [RBD]) are common features of sleep in the alpha-synucleinopathies.
62 es, positioning this approach to treat human alpha-synucleinopathies.
63 R-7 as a therapeutic target for PD and other alpha-synucleinopathies.
64 e-linked aggregation of alpha-Syn in various alpha-synucleinopathies.
65 on of alpha-syn inclusions in PD and related alpha-synucleinopathies.
66 erapies for PD and related neurodegenerative alpha-synucleinopathies.
67 erative disorders, including tauopathies and alpha-synucleinopathies.
70 distinguish alpha-synucleinopathies from non-alpha-synucleinopathies and controls was 84% (sensitivit
71 g REM sleep, is an early clinical symptom of alpha-synucleinopathies and defines a more severe subtyp
72 patients with Parkinson's disease and other alpha-synucleinopathies and demonstrated that NUB1, as w
73 ation between OH and cognitive impairment in alpha-synucleinopathies and discuss possible mechanisms
74 iciency prevented the gut-to-brain spread of alpha-synucleinopathy and associated neurodegeneration a
75 rotein epsilon status, presence of infarcts, alpha-synucleinopathy and neuronal loss in substantia ni
76 hat synphilin-1 can diminish the severity of alpha-synucleinopathy and play a neuroprotective role ag
77 nship between OH and cognitive impairment in alpha-synucleinopathies, and 'indirect-evidence studies'
78 ty (DCS) were studied in prodromal and overt alpha-synucleinopathies, and their relationships with Da
82 h Lewy body disorders with autopsy-confirmed alpha synucleinopathy (as of Oct 1, 2015) who were previ
84 Here we describe a new Drosophila model of alpha-synucleinopathy based on widespread expression of
85 PC12 neuronal cell line, which was conferred alpha-synucleinopathy by inducible expression of alphaSy
86 Lewy bodies, and multiple system atrophy are alpha-synucleinopathies characterized by filamentous alp
89 napse in dementia with Lewy bodies and other alpha-synucleinopathies, direct evidence for the precise
90 hese populations differ in when they exhibit alpha-synucleinopathies during PD pathogenesis, they cou
91 Noting that DMV neurons display extensive alpha-synucleinopathies earlier than SN dopamine neurons
92 g pathophysiology and clinical management of alpha-synucleinopathy, especially for impulse control be
93 Currently, the exact reasons why different alpha-synucleinopathies exhibit variable pathologies and
95 OH and cognitive impairment in patients with alpha-synucleinopathies exists, but the underlying mecha
96 Multiple system atrophy (MSA) is a severe alpha-synucleinopathy facilitated by glial reactions; th
97 e screened the cerebella of 12 patients with alpha-synucleinopathies for neuropathological changes.
99 nostic tool to help clinicians differentiate alpha-synucleinopathies from other forms of parkinsonism
100 centre as a random effect, we observed that alpha-synucleinopathies, frontotemporal lobar degenerati
103 -binding protein 43 immunoreactive deposits, alpha-synucleinopathies, hippocampal sclerosis and prion
104 evere depression to suggest a prodrome of an alpha-synucleinopathy, hypnopompic or hypnagogic halluci
105 purified from Parkinson's disease and other alpha-synucleinopathies, identifying many new alpha-Syn
107 y could have prospect in the amelioration of alpha-synucleinopathy in PD and other Lewy body diseases
108 Here, we test this postulate by assessing alpha-synucleinopathy in the brain in a novel gut-to-bra
111 hich underlies Parkinson's disease and other alpha-synucleinopathies, in a conformation- and phosphor
112 earliest and most specific prodromes of the alpha-synucleinopathies including Parkinson's disease (P
113 he most reliable prodromal biomarker for the alpha synucleinopathies, including Parkinson's disease a
114 uclein (alpha-syn) aggregation characterizes alpha-synucleinopathies, including Parkinson's disease (
116 he brains of patients with neurodegenerative alpha-synucleinopathies, including Parkinson's disease.
118 Nigrostriatal dopaminergic degeneration in alpha-synucleinopathies is indirectly reflected by low d
119 vation of phospho-eIF2alpha, indicating that alpha-synucleinopathy is associated with abnormal UPR th
122 synuclein in Parkinson's disease and related alpha-synucleinopathies lead to neuronal dysfunction and
125 atal deletion of Bmal1 in mouse tauopathy or alpha-synucleinopathy models unexpectedly suppresses bot
126 ith Lewy bodies and in the pre-formed fibril alpha-synucleinopathy mouse model, that specific classes
127 ein conformers cause at least three distinct alpha-synucleinopathies: multiple system atrophy (MSA),
129 standing of the clinical heterogeneity among alpha-synucleinopathies, offers an opportunity for a spe
130 isk factors, imaging changes associated with alpha-synucleinopathy, or physical findings of parkinson
131 twork alterations in oligodendrocytes in the alpha-synucleinopathies Parkinson's disease and multiple
132 ior disorder (RBD) in patients who developed alpha-synucleinopathies (Parkinson disease, dementia wit
133 e lifetime incidence was 53 times greater in alpha-synucleinopathy patients than in controls (odds ra
134 With 53 times greater lifetime incidence in alpha-synucleinopathy patients than in controls, RBD was
135 bserved in the substantia nigra of prodromal alpha-synucleinopathy patients with positive DaT-SPECT c
137 d RBD who eventually phenoconverted to overt alpha-synucleinopathy (RBD due to synucleinopathy) were
138 d combined negative effects on disability in alpha-synucleinopathies, reflecting a 'malignant' phenot
141 s with Alzheimer's disease and patients with alpha-synucleinopathy showed relatively lower burdens of
142 tion in Parkinson's disease (PD) and related alpha-synucleinopathies.SIGNIFICANCE STATEMENT Autophagy
145 family study method was used to measure the alpha-synucleinopathy spectrum features, which included
146 o RBD genetics, highlighting RBD as a unique alpha-synucleinopathy subpopulation that will allow futu
147 Urinary urgency and frequency are common in alpha-synucleinopathies such as Parkinson disease, Lewy
149 ays an important role in the pathogenesis of alpha-synucleinopathies such as Parkinson's disease (PD)
150 ntral catecholamine deficiency characterizes alpha-synucleinopathies such as Parkinson's disease.
151 onal inclusions more commonly found in other alpha-synucleinopathies such as Parkinson's disease.
153 auopathies, such as frontotemporal dementia; alpha-synucleinopathies, such as Parkinson's disease or
157 optimizing the distinction between different alpha-synucleinopathies; the selection of subgroups most
158 kin in alpha-synuclein-containing lesions in alpha-synucleinopathies, thereby challenging prior infer
159 scribed mouse models of beta-amyloidosis and alpha-synucleinopathy to explore cerebrospinal fluid (CS
160 sion by using the pre-formed fibril model of alpha-synucleinopathy to induce the seeding and spreadin
161 of Lewy body disorder with autopsy-confirmed alpha synucleinopathy, we identified 49 (23%) patients w
162 recently shown to mimic prodromal stages of alpha-synucleinopathy, we now demonstrate striking REM a
163 aS transgenic (A53TalphaS Tg) mouse model of alpha-synucleinopathy, we show that disease onset in the
164 ach utilizing in vitro and in vivo models of alpha-synucleinopathy, we uncovered an unprecedented rol
165 for dementia due to Alzheimer's disease and alpha-synucleinopathies, which suggests that these disor
167 ccurred at the prodromal and early stages of alpha-synucleinopathy, which have implications for under
168 aused defects in neuronal autophagy prior to alpha-synucleinopathy, which was associated with accumul
169 is facile, synchronized rapid-onset model of alpha-synucleinopathy will be highly valuable in testing